Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update
April 14, 2023 11:10 ET
|
Merus N.V.
- Robust 36% overall response rate (ORR) in 42 evaluable patients - 6 months median duration of response with 17 patients still on treatment as of Nov. 28, 2022 data cutoff - End-of-Phase meeting...
Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023
March 14, 2023 16:30 ET
|
Merus N.V.
– Plenary session oral presentation: Monday, April 17, 2023, 10:15 a.m.-12:15 p.m. ET– Poster presentation on petosemtamab in advanced gastric/esophageal adenocarcinoma: Monday, April 17, 2023,...
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023
March 14, 2023 16:30 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative,...
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update
February 28, 2023 16:25 ET
|
Merus N.V.
– Zenocutuzumab (Zeno) in NRG1+ cancer potential registrational path and timeline update planned for first half of 2023 – Petosemtamab clinical and regulatory update planned for first half of 2023 –...
Merus to Participate in Upcoming Investor Conferences
February 01, 2023 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
November 09, 2022 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus Announces Financial Results for the Third Quarter and Provides Business Update
November 03, 2022 07:51 ET
|
Merus N.V.
– Clinical update of MCLA-129 presented at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics– Zenocutuzumab (Zeno) Regulatory update: FDA recommends additional...
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
October 26, 2022 04:00 ET
|
Merus N.V.
- MCLA-129 observed to be well tolerated with a favorable safety profile - Antitumor activity was observed among heavily pretreated patients, across multiple tumor types and dose levels -...
Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
October 12, 2022 07:00 ET
|
Merus N.V.
– MCLA-129 observed to be well tolerated with preliminary evidence of anti-tumor activity during dose escalation phase – Initial recommended phase two dose set at 1500 mg with dose expansion ongoing ...
Merus Announces Poster Presentation on MCLA-129 at the 34th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics
September 07, 2022 16:10 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...